Gilead Sciences, Inc. (NASDAQ:GILD) shares, rose in value, with the stock price down by -2.70% to the previous day’s close as strong demand from buyers drove the stock to $65.27.
Actively observing the price movement in the last trading, the stock closed the session at $67.08. The PE ratio was 14.49 over 12-month period. Referring to stock’s 52-week performance, its high was $87.86, and the low was $65.90. On the whole, GILD has fluctuated by -9.86% over the past month.
The company’s Forward Dividend Ratio is 3.02, with its dividend yield at 4.63%.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 25.69B, with a low estimate of 5.58B and a high estimate of 6.33B. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 5.92B.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that GILD’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 2.70, with the price of GILD currently trading nearly -5.50% and -8.84% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 24.70, while the 7-day volatility ratio is showing 1.76% which for the 30-day chart, stands at 1.52%. Furthermore, Gilead Sciences, Inc. (GILD)’s beta value is 0.22, and its average true range (ATR) is 1.11.
A comparison of Gilead Sciences, Inc. (GILD) with its peers suggests the former has fared considerably weaker in the market. GILD showed an intraday change of -2.70% in last session, and over the past year, it shrunk by -23.74%%.
Data on historical trading for Gilead Sciences, Inc. (NASDAQ:GILD) indicates that the trading volumes over the past 3 months, they’ve averaged 7.21 million. According to company’s latest data on outstanding shares, there are 1.25 billion shares outstanding.
Nearly 0.10% of Gilead Sciences, Inc.’s shares belong to company insiders and institutional investors own 85.82% of the company’s shares. The stock has fallen by -19.43% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the GILD stock heading into the next quarter.
